Navigation Links
Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
Date:2/9/2009

MENLO PARK, Calif., Feb. 9 /PRNewswire/ -- Artemis Health Inc., a privately-held company dedicated to the development of non-invasive prenatal diagnostic tests, today announced that Richard Rava, Ph.D., has joined Artemis Health in the newly created position of senior vice president of research and development.

"Rich's depth and breadth of research, development and manufacturing experience, together with his proven track record in commercializing genetic analysis tools, makes him uniquely suited to lead our efforts to bring non-invasive prenatal diagnostic tests to the market," said Lissa Goldenstein, president and chief executive officer of Artemis Health.

Dr. Rava brings more than 20 years of research, development and operational expertise in molecular and genetic analysis for commercial assays and instrumentation. He comes to Artemis after 16 years at Affymetrix where he was a scientific co-founder and most recently senior vice president of research and development. During his tenure, Dr. Rava led the research, development and manufacturing scale-up of the Affymetrix' GeneChip(R) technology. He was responsible for the delivery of multiple products involving complex assays, microarrays, instrumentation and software that applied scientific technology to meet the needs of the gene expression, genetics research and clinical markets.

Prior to co-founding Affymetrix, Dr. Rava served as a senior scientist at Affymax Research Institute. From 1990 through 1992, he served as principal research scientist at the George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology (MIT). During that time, he was also the research coordinator for the National Institute of Health Laser Biomedical Research Center at MIT. Dr. Rava has published over 60 papers in peer-reviewed scientific publications and is an author on over 30 issued U.S. patents. He received his B.A. and Ph.D., in chemistry from Rutgers University.

"Artemis Health is the only company focused exclusively on the development of non-invasive prenatal tests to determine genetic abnormalities using both intact cell and cell-free fetal DNA analysis tools," remarked Dr. Rava. "I am extremely excited to join this highly-committed team, and look forward to playing an active role in the rapidly evolving field of prenatal diagnostics."

The Artemis Advantage for Prenatal Testing

Prenatal testing is an important tool for most pregnancies in the United States and the rest of the developed world. While the results of these tests provide timely information about the well-being of the fetus, it is broadly agreed that a safer prenatal diagnostic test offered early would allow women and their families to make more informed decisions about their pregnancy and better prepare for potential problems in their infants.

Artemis Health is developing non-invasive, genome-based prenatal tests for use in early pregnancy to diagnose genetic abnormalities and chromosomal aneuploidies (abnormal number of chromosomes). Through a single maternal blood draw early in pregnancy, Artemis' diagnostic tests are being designed to isolate intact fetal cells and cell-free fetal DNA to provide valuable and accurate genetic information without risk to the mother or her baby.

About Artemis Health Inc.

Artemis Health Inc. is a privately-held, diagnostics company focused on the development of non-invasive early-pregnancy prenatal tests for use in all pregnant women. Working in collaboration with leading research and clinical institutions, the company has developed cutting-edge technology to transform the field of prenatal testing through the analysis of both whole-cell and cell-free fetal DNA isolated from maternal blood. With a single, maternal blood draw early in pregnancy, Artemis' diagnostic tests are being designed to provide women with an accurate alternative to the invasive methods of amniocentesis and chorionic villus sampling available today. For more information about Artemis Health, please visit http://www.artemishealthinc.com.


'/>"/>
SOURCE Artemis Health Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exelixis Sells 80% Stake in Artemis to Taconic
2. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
3. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
10. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox ... response to client demand KbioBox developed a sophisticated “3 click” gene dditing off ... accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by the ...
(Date:12/8/2016)... ... ... This CAST literature review and report looks at problems caused by the current ... in countries that are major global commodity exporters and importers, which show that asynchrony ... level presence (LLP) puts large volumes of trade worth billions of dollars at risk. ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):